2023 ACCP Virtual Journal Club Webinar-August | Impact of Multiple Concomitant CYP3A Inhibitors on Venetoclax Pharmacokinetics: A PBPK and Population PK-Informed Analysis | ON DEMAND
2023 ACCP Virtual Journal Club Webinar: Impact of Multiple Concomitant CYP3A Inhibitors on Venetoclax Pharmacokinetics: A PBPK and Population PK-Informed Analysis | ON DEMAND
On Demand webinar recording: August 16th, 2023 to August 16th, 2026
Why is this article important to your practice?
Venetoclax is an approved BCL-2 inhibitor that is primarily metabolized by cytochrome P450 3A (CYP3A). Although venetoclax exposure has been well characterized with one concomitant CYP3A inhibitor, complex drug-drug interactions involving more than one inhibitor have not been systematically evaluated despite the common polypharmacy in the target populations. In this webinar, the author will leverage physiologically-based pharmacokinetic (PBPK) and population pharmacokinetic (PK) modeling to describe the potential impact of multiple concomitant CYP3A inhibitors on venetoclax pharmacokinetics. The modeling approaches were informed by clinical data in the presence of single or multiple CYP3A inhibitors and the effects of one or more inhibitors were systematically evaluated within these modeling frameworks. Learners that complete this activity will be able to describe the potential impact of multiple concomitant CYP3A inhibitors on venetoclax pharmacokinetics using PBPK and population PK modeling.
Physicians, Pharmacists, PhDs and other healthcare professionals interested in PBPK/PopPK modeling, drug-drug interactions.
After completing this activity, the learner will be able to:
- Describe the rationale to assess and quantify the potential impact of multiple concomitant CYP3A inhibitors on venetoclax pharmacokinetics;
- Describe the approaches and validation procedures used to inform dose adjustment for co-administration of venetoclax with multiple CYP3A inhibitors;
- Describe the benefits and limitations of these approaches to identify the potential impact of multiple concomitant medications in the development of new agents.
Ahmed Salem, PhD
Dr. Ahmed Salem is a Senior Research Fellow of Clinical Pharmacology at Abbvie and an adjunct Professor at University of Minnesota. Dr. Salem got his PhD in Clinical Pharmacology in 2010 from the University of Minnesota with a focus on Pharmacometrics and a minor in Biostatistics. His research at UMN focused on Pharmacometric Applications in Infectious Diseases. At Abbvie, Dr Salem has led the clinical pharmacology, pharmacometrics and biopharmaceutics strategy of several small and large molecules in oncology, virology, and women’s health. He contributed to 14 different FDA and EMA approvals of new drugs, dosage forms or dosage regimens. He has worked on over 180 Phase I, II and III clinical trials. He has over 200 publications with an i-10 index of 114 and H index of 40 and holds seven patents in the USA and EU.
Recently, the American College of Clinical Pharmacology (ACCP) selected Dr Salem as the 2022 recipient of the prestigious Tanabe Investigator Award. He was also the 2018 recipient of the High Impact Article Award by the American Association of Pharmaceutical Scientists (AAPS) in addition to other awards and recognition from the IQ-Clinical Pharmacology Leadership Group (CPLG), UMN and
AbbVie Inc. Dr. Salem has also been an invited speaker and chair at multiple conferences such as the American Society for Clinical Pharmacology & Therapeutics (ASCPT), ACCP and Accelerating Anti-Cancer Agent Development & Validation (AAADV). He also recently established a joint industry-academia postdoctoral fellowship in clinical pharmacology and pharmacometrics between Abbvie and University of Minnesota.
Ahmed Hamed Salem, PhD, Director, AbbVie Inc is an employee at AbbVie Inc. All of the relevant financial relationships for this individual have been mitigated.